SwedenBIO, one of Europe´s biggest industry organizations with over 180 exciting member companies in Sweden, revealed in its latest report that the total number of Swedish life science and biotechnology companies with projects in clinical phase has doubled since six years ago.
The only national organization working for the benefit of the entire life science industry in Sweden has asked Swedish companies focused on research and development about their drug pipeline status each year since 2006. In 2012, 42 projects were reported to be in clinical phase, nearly twice as compared to in 2006.
Gilead Sciences, Inc. (NASDAQ:GILD) edged down Monday as the new Abbott Laboratories (NYSE:ABT) results, together with new hepatitis C drug data from Bristol Myers Squibb Co. (NYSE:BMY), suggest Gilead continues to face strong rivalry to its perceived status as the leader in the hepatitis C race.
Shares of this company traded down -0.91% during trading yesterday, hitting $69.19. The stock has a 52 week low of $34.45 and a 52 week high of $70.39. The company has a market cap of $50.93 billion and a P/E ratio of 20.40. The P/S ratio is 5.65 and P/B ratio 6.36. The beta value is 0.44. GILD’s RSI amounts to 58.40.
Illumina, Inc. (NASDAQ:ILMN) plunged facing the worst intraday fall since Oct. 7, 2011 as investors weighed concerns that Roche Holding AG will renew its interest in buying the world’s biggest maker of DNA sequencing equipment. The company has a market value of $5.91 billion.
It employs 2,200 people, over the last 12 months has generated revenue of $1.04 billion and has a net income of $81.47 million. The firm’s operating margin is 15.08 percent and net profit margin 7.84 percent. The latest closing price of its shares moved up 5.62% from the 50-day moving average.
Sarepta Therapeutics Inc (NASDAQ:SRPT) closed up yesterday after analysts at Wedbush reiterated their outperform rating on the stock. For this company, a return on equity of -52.37 percent was realized due to the financial situation.
Last twelve months earnings per share reached a value of -$0.67. Earnings are projected to move up 20.00 percent for the coming five years. The stock closed at $27.36, up 0.25 points or 0.92% from previous close and at a distance of +20.91% from 20-day simple moving average.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) gained after lately commenced a phase I multiple dose study with APD811. While trading at volume higher than average, the stock climbed 1.31% yesterday.
Its previous 52-week high was $13.50 and moved up 551.41% over the same period, trading at a volume of 5.30 million. Shares have risen 261.33% over the trailing 6 months. The stock is currently trading 9.15% above its SMA 50 and 65.59% above its SMA 200.